Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec (Singapore) Pte Ltd
460 Alexandra Road #15-01
PSA Building
Singapore 119963
Singapore
Phone: +65 6876 4588
Fax: +65 6876 4599
Simranjit Singh highlights Guardant Health’s role in the global precision oncology landscape and how the company leverages its proprietary blood tests, vast data sets, and advanced analytics across the huge…
John Baby of home rehabilitation device start-up WO:EX outlines how his firm’s products differ from others on the market through their multifunctionality, its expansion plans in Asia and Australia, and…
Dr Varun Sethi outlines some of the most important trends in ASEAN healthcare today and how DKSH, as a historic business services provider, is adapting its offering to meet them.…
Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative life sciences start-ups and spin-offs has dramatically increased. These companies…
Annie Tan highlights the strategy she laid out to navigate the BMS Singapore, Thailand and Malaysia affiliates through the COVID-19 pandemic; the opportunities and challenges of integrating the Celgene portfolio…
Kenneth Tan has been President for Asia Pacific & Japan at cancer-focused medical device player Varian since February 2019. In a recent conversation with PharmaBoardroom, Tan shared how an early…
Professor Ng Huck Hui of A*Star’s Biomedical Research Council outlines the evolution of Singapore’s science and technology research and innovation ecosystem over the past 20 years and why the country…
Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in 2015, their proprietary Rational Antibody Discovery (RAD) technology platform, and…
UPS APAC’s Bee Lim describes how the logistics giant responded to the unprecedented challenges thrown up by the COVID-19 pandemic, the trends that the pandemic has accelerated in the region,…
Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy has evolved, why Singapore is still a logical base,…
Clarence Ngui describes how global orthopaedic product giant Zimmer Biomet has pivoted in APAC in response to the COVID-19 pandemic; how medical education needs differ across the vast APAC region;…
Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a…
See our Cookie Privacy Policy Here
